A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma.

Trial Profile

A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Bortezomib; Rituximab
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 12 May 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Mar 2012 Actual initiation date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top